Journal
FEBS LETTERS
Volume 583, Issue 13, Pages 2157-2159Publisher
WILEY
DOI: 10.1016/j.febslet.2009.05.052
Keywords
alpha-Glucosidase inhibitors; Type 2 diabetes; Hydrogen gas; Antioxidant
Funding
- Japan Science and Technology Agency
Ask authors/readers for more resources
The major side-effect of treatment with alpha-glucosidase inhibitors, flatulence, occurs when undigested carbohydrates are fermented by colonic bacteria, resulting in gas formation. We propose that the cardiovascular benefits of alpha-glucosidase inhibitors are partly attributable to their ability to neutralise oxidative stress via increased production of H-2 in the gastrointestinal tract. Acarbose, which is an alpha-glucosidase inhibitor, markedly increased H-2 production, with a weaker effect on methane production. Our hypothesis is based on our recent discovery that H-2 acts as a unique antioxidant, and that when inhaled or taken orally as H-2-dissolved water it ameliorates ischaemia-reperfusion injury and atherosclerosis development. (C) 2009 Federation of European Biochemical Societies. Published by Elsevier B. V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available